Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Rating of “Moderate Buy” by Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has earned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $19.00.

Several analysts have commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th. Needham & Company LLC restated a “buy” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, October 17th. HC Wainwright increased their price target on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th. Finally, Wedbush upped their price objective on Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a report on Friday, October 17th.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Ground Swell Capital LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth about $38,000. Y Intercept Hong Kong Ltd acquired a new position in Artiva Biotherapeutics during the second quarter valued at approximately $48,000. Marshall Wace LLP purchased a new stake in Artiva Biotherapeutics during the second quarter worth approximately $79,000. Qube Research & Technologies Ltd acquired a new stake in shares of Artiva Biotherapeutics in the second quarter worth $58,000. Finally, Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter valued at $67,000.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $4.42 on Friday. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $7.46. The company has a market capitalization of $108.49 million, a PE ratio of -1.71 and a beta of 2.92. The stock has a fifty day moving average of $3.98 and a two-hundred day moving average of $3.35.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, equities research analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.